Phathom Pharmaceuticals’ Finance Vice President To Leave December 4

Robert Breedlove will keep his finance and accounting roles until his departure, which Phathom said was unrelated to a disagreement.

Share
Phathom Pharmaceuticals’ Finance Vice President To Leave December 4

Phathom Pharmaceuticals, which sells treatments for gastrointestinal diseases, will lose its finance vice president and principal accounting officer, Robert Breedlove, on December 4. Breedlove gave notice Thursday of his decision to resign, according to the company’s SEC filing Wednesday.

Breedlove Keeps Both Roles Until Departure

Breedlove will remain in charge of his existing finance and accounting roles through the effective date of his resignation. His notice sets a future departure date; he continues to serve as vice president of finance and principal accounting officer in the meantime.

Phathom said the resignation was unrelated to any disagreement about its operations, policies or practices.

VOQUEZNA Anchors The U.S. Business

Phathom is a commercial-stage biopharmaceutical company whose business centers on treatments for gastrointestinal diseases. Its approved products are VOQUEZNA tablets, VOQUEZNA DUAL PAK and VOQUEZNA TRIPLE PAK, according to its annual report for the fiscal year ended December 31, 2025.

Each contains vonoprazan, a medicine that suppresses the secretion of stomach acid. The products have approvals covering erosive and non-erosive gastroesophageal reflux disease, commonly called GERD, and Helicobacter pylori infection.

The company earns all its revenue from U.S. sales of these products. Pharmaceutical wholesale distributors and selected pharmacies are its main buyers, and VOQUEZNA accounted for most of revenue in 2025.

That places the finance and accounting departure at a company already selling approved medicines, supported by a U.S. distribution business. The commercial figures in its annual report describe the reach of those treatments: more than 1.1 million prescriptions had been filled since launch as of February 13, 2026.

Coverage at that same date extended to more than 120 million people under U.S. commercial health plans. Both figures are dated measures of Phathom’s commercial reach, alongside a revenue base drawn entirely from its gastrointestinal products.

Breedlove’s resignation is scheduled to take effect December 4, 2026.

Sources

More on Phathom Pharmaceuticals

All Phathom Pharmaceuticals (PHAT) coverage →